ID
36487
Description
Pilot Study of Atorvastatin for Orthopedic Surgery Patients; ODM derived from: https://clinicaltrials.gov/show/NCT02197065 Brief Summary: Up to 35% of hip fracture patients have been shown to experience heart injury after surgery, and as many as 10% have a heart attack or die in the three months after surgery. Hip and knee arthroplasty patients are also at risk of cardiovascular complications. Patients who have these complications have higher levels of inflammation postoperatively. Statins (such as atorvastatin/Lipitor) lower cholesterol and also lessen inflammation. Both of these effects are important in preventing heart attacks. Statins have been shown to reduce the risk of heart attacks in non-surgical patients, and to protect from heart attacks in patients having heart surgery. Whether statins can prevent heart attacks in orthopedic patients is not known. In this pilot study the investigators will treat 30 orthopedic surgery patients (hip fracture, hip or knee arthroplasty) with either atorvastatin or placebo (a capsule with no study drug). Patients will start the study drug prior to surgery and take it for 45 days after surgery. Neither the doctors nor the patients will know whether they are taking atorvastatin or placebo. The investigators will look for evidence of inflammation and heart injury after surgery. The investigators hypothesize that atorvastatin will lessen the degree of postoperative inflammation found in these patients. In this study, the investigators will use a very sensitive test of heart injury that can detect problems even when patients have no symptoms. The investigators hypothesize that this test will demonstrate silent heart injury in over 50% of the hip fracture patients and over 30% of arthroplasty patients in our study. The results of this trial will help us to develop a larger study in 1000 hip fracture and joint replacement patients to determine whether atorvastatin protects orthopedic surgery patients from heart injury and other complications of surgery.
Lien
https://clinicaltrials.gov/show/NCT02197065
Mots-clés
Versions (1)
- 17/05/2019 17/05/2019 -
Détendeur de droits
Hospital for Special Surgery, New York
Téléchargé le
17 mai 2019
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY-NC 3.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Atorvastatin as Post-OP NCT02197065
Eligibility Criteria
- StudyEvent: Eligibility
Similar models
Eligibility Criteria
- StudyEvent: Eligibility
C0392806 (UMLS CUI [2])
C0086511 (UMLS CUI [3])
C0016663 (UMLS CUI [1,2])
C0678226 (UMLS CUI [1,3])
C0006826 (UMLS CUI [1,4])
C0360714 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,3])
C0360714 (UMLS CUI [1,2])
C0002965 (UMLS CUI [2])
C0027051 (UMLS CUI [1,2])
C0262926 (UMLS CUI [2,1])
C0948089 (UMLS CUI [2,2])
C0262926 (UMLS CUI [3,1])
C0002962 (UMLS CUI [3,2])
C0262926 (UMLS CUI [4,1])
C0027056 (UMLS CUI [4,2])
C1704436 (UMLS CUI [1,2])
C0262926 (UMLS CUI [1,2])
C0007787 (UMLS CUI [1,3])
C0019557 (UMLS CUI [2,1])
C0262926 (UMLS CUI [2,2])
C0038454 (UMLS CUI [2,3])
C0012634 (UMLS CUI [1,2])
C0205404 (UMLS CUI [1,2])
C0151905 (UMLS CUI [2,1])
C0205250 (UMLS CUI [2,2])
C0205404 (UMLS CUI [1,2])
C0151577 (UMLS CUI [2])
C0162714 (UMLS CUI [1,2])
C0087111 (UMLS CUI [2,1])
C0019196 (UMLS CUI [2,2])
C0033607 (UMLS CUI [2,3])
C0055856 (UMLS CUI [2])
C0027996 (UMLS CUI [3])
C0360363 (UMLS CUI [4])
C0006147 (UMLS CUI [2])
C0032992 (UMLS CUI [3])